Drug intelligence / Profile preview

ovarian cancer vaccine

Development stage: Preclinical
Lead developer: Anixa Biosciences
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous, Intranodal, Intraperitoneal, Intravenous, Transdermal, Oral, Intramuscular, Lymph Node Injection, Intranasal, Electroporation

Overview

The ovarian cancer vaccine is a novel immunotherapy developed by Cleveland Clinic and exclusively licensed worldwide to Anixa Biosciences. This vaccine is designed to prevent ovarian cancer by stimulating the immune system to recognize and target "retired" proteins that are re-expressed in cancer cells. The technology aims to prevent tumor formation by eliciting an immune response against these specific cancer-associated proteins. Anixa Biosciences is collaborating with Cleveland Clinic on its development, which is currently in preclinical stages.

Beyond the preview

Go deeper on ovarian cancer vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ovarian cancer vaccine.

Explore the full profile